$BIOLQ
BIOLASE, INC

2019 Form 10-K Financial Statement

#000156459020013794 Filed on March 30, 2020

View on sec.gov

Income Statement

Concept 2019 2018 Q4 2017 Q4
Revenue $37.80M $13.05M $12.63M
YoY Change -18.1% 3.33% -8.21%
Cost Of Revenue $23.51M $7.430M $9.020M
YoY Change -19.65% -17.63% 7.89%
Gross Profit $14.29M $5.610M $3.610M
YoY Change -15.43% 55.4% -33.15%
Gross Profit Margin 37.8% 42.99% 28.58%
Selling, General & Admin $25.14M $8.160M $6.440M
YoY Change -15.88% 26.71% -10.8%
% of Gross Profit 175.98% 145.45% 178.39%
Research & Development $4.765M $1.280M $1.390M
YoY Change -8.42% -7.91% -39.57%
% of Gross Profit 33.35% 22.82% 38.5%
Depreciation & Amortization $982.0K $240.0K $310.0K
YoY Change 3.92% -22.58% 14.81%
% of Gross Profit 6.87% 4.28% 8.59%
Operating Expenses $29.91M $9.440M $7.830M
YoY Change -20.83% 20.56% -17.75%
Operating Profit -$15.60M -$3.830M -$4.220M
YoY Change -25.31% -9.24% 2.43%
Interest Expense $2.157M -$440.0K $190.0K
YoY Change -478.42% -331.58% -167.86%
% of Operating Profit
Other Income/Expense, Net $2.278M
YoY Change
Pretax Income -$17.90M -$6.950M -$4.540M
YoY Change -16.55% 53.08% 3.42%
Income Tax -$44.00K $570.0K -$21.79M
% Of Pretax Income
Net Earnings -$17.86M -$6.920M -$3.840M
YoY Change -17.02% 80.21% -13.32%
Net Earnings / Revenue -47.24% -53.03% -30.4%
Basic Earnings Per Share -$0.77
Diluted Earnings Per Share -$0.77 -$333.7K -$229.8K
COMMON SHARES
Basic Shares Outstanding 23.20M 20.65M
Diluted Shares Outstanding 23.20M

Balance Sheet

Concept 2019 2018 Q4 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.790M $8.040M $11.65M
YoY Change -27.99% -30.99% 30.61%
Cash & Equivalents $5.790M $8.044M $11.65M
Short-Term Investments
Other Short-Term Assets $1.470M $1.900M $1.980M
YoY Change -22.63% -4.04% 12.5%
Inventory $11.00M $12.25M $12.30M
Prepaid Expenses
Receivables $8.760M $11.11M $10.12M
Other Receivables $0.00 $51.00K $6.000K
Total Short-Term Assets $27.02M $33.31M $36.05M
YoY Change -18.88% -7.61% 6.07%
LONG-TERM ASSETS
Property, Plant & Equipment $1.470M $1.975M $3.674M
YoY Change -25.76% -46.24% -17.95%
Goodwill $2.926M $2.926M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $430.0K $308.0K $334.0K
YoY Change 38.71% -7.78% -39.27%
Total Long-Term Assets $4.830M $5.209M $6.934M
YoY Change -7.29% -24.88% -12.81%
TOTAL ASSETS
Total Short-Term Assets $27.02M $33.31M $36.05M
Total Long-Term Assets $4.830M $5.209M $6.934M
Total Assets $31.85M $38.52M $42.98M
YoY Change -17.32% -10.39% 2.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.330M $5.953M $5.110M
YoY Change -10.42% 16.5% -44.03%
Accrued Expenses $3.790M $7.538M $4.690M
YoY Change -38.17% 60.72% -1.68%
Deferred Revenue $2.476M $2.625M
YoY Change -5.68%
Short-Term Debt $13.47M $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $25.78M $15.97M $13.37M
YoY Change 61.43% 19.42% -25.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $10.84M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.650M $100.0K $169.0K
YoY Change 200.0% -40.83% -36.94%
Total Long-Term Liabilities $1.650M $10.94M $169.0K
YoY Change -85.51% 6371.01% -36.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.78M $15.97M $13.37M
Total Long-Term Liabilities $1.650M $10.94M $169.0K
Total Liabilities $27.51M $27.43M $13.72M
YoY Change 0.29% 99.85% -30.95%
SHAREHOLDERS EQUITY
Retained Earnings -$216.7M -$195.2M
YoY Change 11.02% 9.45%
Common Stock $228.5M $225.0M
YoY Change 1.53% 11.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.340M $11.09M $29.26M
YoY Change
Total Liabilities & Shareholders Equity $31.85M $38.52M $42.98M
YoY Change -17.32% -10.39% 2.48%

Cashflow Statement

Concept 2019 2018 Q4 2017 Q4
OPERATING ACTIVITIES
Net Income -$17.86M -$6.920M -$3.840M
YoY Change -17.02% 80.21% -13.32%
Depreciation, Depletion And Amortization $982.0K $240.0K $310.0K
YoY Change 3.92% -22.58% 14.81%
Cash From Operating Activities -$12.75M -$3.560M -$4.250M
YoY Change -9.9% -16.24% 34.92%
INVESTING ACTIVITIES
Capital Expenditures $207.0K -$450.0K $80.00K
YoY Change -62.9% -662.5% -122.86%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$207.0K -$450.0K $80.00K
YoY Change -60.34% -662.5% -122.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.171M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.72M 10.01M 11.35M
YoY Change -4.57% -11.81% -22800.0%
NET CHANGE
Cash From Operating Activities -12.75M -3.560M -4.250M
Cash From Investing Activities -207.0K -450.0K 80.00K
Cash From Financing Activities 10.72M 10.01M 11.35M
Net Change In Cash -2.255M 6.000M 7.180M
YoY Change -36.3% -16.43% -302.25%
FREE CASH FLOW
Cash From Operating Activities -$12.75M -$3.560M -$4.250M
Capital Expenditures $207.0K -$450.0K $80.00K
Free Cash Flow -$12.95M -$3.110M -$4.330M
YoY Change -11.91% -28.18% 54.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Inventory Net
InventoryNet
10995000
CY2018Q4 us-gaap Inventory Net
InventoryNet
12248000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5953000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8044000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
312000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
312000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8760000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11112000
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Security12b Title
Security12bTitle
Common stock at par value $0.001 per share
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5789000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1163000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1591000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
27019000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
33307000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1193000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1975000
CY2019Q4 us-gaap Goodwill
Goodwill
2926000
CY2018Q4 us-gaap Goodwill
Goodwill
2926000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
276000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
308000
CY2018Q4 us-gaap Assets
Assets
38516000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
51000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
169500000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
111300000
CY2019Q4 us-gaap Liabilities
Liabilities
27505000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-701000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1045000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
100000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7538000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2476000
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
78000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
77000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
358000
CY2018Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
447000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10836000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21972000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21972000
CY2019 biol Products And Services Revenue
ProductsAndServicesRevenue
37787000
CY2018 biol Products And Services Revenue
ProductsAndServicesRevenue
46143000
CY2017 biol Products And Services Revenue
ProductsAndServicesRevenue
46798000
CY2019 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
12000
CY2018 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
12000
CY2017 biol License Fees And Royalty Revenue
LicenseFeesAndRoyaltyRevenue
128000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37799000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46155000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
46926000
CY2019 us-gaap Cost Of Revenue
CostOfRevenue
23511000
CY2018 us-gaap Cost Of Revenue
CostOfRevenue
29260000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
3965000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
21000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
235594000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
228430000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-670000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-234547000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216692000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
11089000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38516000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
850000
CY2018Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2018Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2017 us-gaap Cost Of Revenue
CostOfRevenue
31800000
CY2019 us-gaap Gross Profit
GrossProfit
14288000
CY2018 us-gaap Gross Profit
GrossProfit
16895000
CY2017 us-gaap Gross Profit
GrossProfit
15126000
CY2019 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14396000
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
18121000
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16718000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11771000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9712000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6229000
CY2018 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-1185000
CY2017 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
-505000
CY2018 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-1500000
CY2018 us-gaap Operating Expenses
OperatingExpenses
37780000
CY2017 us-gaap Operating Expenses
OperatingExpenses
33164000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-18038000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
377000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31847000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2531000
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
70000
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
70000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31439144
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31439144
CY2017 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
3978000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2145000
CY2017 biol Stock Issued During Period Value Rights Offering Net
StockIssuedDuringPeriodValueRightsOfferingNet
11358000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
29260000
CY2018 biol Adjustments To Additional Paid In Capital Fees For Rights Offering
AdjustmentsToAdditionalPaidInCapitalFeesForRightsOffering
38000
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
847000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4250000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2395000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
364000
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
161000
CY2017 biol Convertible Preferred Stock And Warrants Issuance Cost
ConvertiblePreferredStockAndWarrantsIssuanceCost
251000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
920000
CY2019 us-gaap Profit Loss
ProfitLoss
-17855000
CY2018 us-gaap Profit Loss
ProfitLoss
-21516000
CY2017 us-gaap Profit Loss
ProfitLoss
-16851000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
945000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1203000
CY2018 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-1228000
CY2017 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-505000
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
469000
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
40000
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
166000
CY2017 us-gaap Inventory Write Down
InventoryWriteDown
623000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
22065000
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
140000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
202000
CY2019 biol Gain Loss On Issuance Of Warrants To Consultants
GainLossOnIssuanceOfWarrantsToConsultants
-48000
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
7000
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-27000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-694000
CY2019 biol Earned Interest Income
EarnedInterestIncome
-2000
CY2018 biol Earned Interest Income
EarnedInterestIncome
-1000
CY2017 biol Earned Interest Income
EarnedInterestIncome
42000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-655000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1458000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
337000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-840000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
127000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-419000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-439000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
25000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3156000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1762000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5077000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
114000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-161000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-397000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12746000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14147000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18412000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
207000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
558000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
747000
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
36000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-207000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-522000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-747000
CY2018 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
46000
CY2017 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
146000
CY2018 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
3696000
CY2018 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
3696000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2500000
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
12500000
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
133000
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1058000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9171000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21761000
CY2019 biol Payments Of Fees For Shelf Registration
PaymentsOfFeesForShelfRegistration
821000
CY2018 biol Payments Of Fees For Shelf Registration
PaymentsOfFeesForShelfRegistration
164000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4000
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3000
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
3000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10721000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11235000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21618000
CY2019 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-23000
CY2018 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-106000
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
262000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2255000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3540000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2721000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8356000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11896000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9175000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6101000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
1784000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
23000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
1000
CY2017 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
74000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
35000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
44000
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
164000
CY2019 biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
797000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
18000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
102000
CY2018 biol Non Cash Loss On Patent Litigation Settlement
NonCashLossOnPatentLitigationSettlement
1500000
CY2019 biol Non Cash Settlement Restricted Stock Unit Award Liability
NonCashSettlementRestrictedStockUnitAwardLiability
201000
CY2019 biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Liability
NonCashRightOfUseAssetsObtainedInExchangeForLeaseLiability
276000
CY2019 biol Non Cash Equity Financing Costs In Accounts Payable
NonCashEquityFinancingCostsInAccountsPayable
129000
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
161000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
847000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates. </p>
CY2019 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers&#8217; financial condition and maintains relationships with the Company&#8217;s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of products. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s revenue is denominated in U.S.&#160;dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company&#8217;s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the years ended December 31, 2019, 2018, and 2017, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S.&#160;dollar may affect the price competitiveness of the Company&#8217;s products outside the U.S.</p>
CY2019Q4 biol Working Capital
WorkingCapital
14700000
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2
CY2019 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At the Company’s annual meeting of stockholders on May 9, 2018 (the “2018 Annual Meeting”), the Company’s stockholders approved an amendment to its Restated Certificate of Incorporation to effect a reverse stock split of its common stock, at a ratio ranging from one-for-five to one-for-fifteen, with the final ratio to be determined by the Company’s board of directors (the “Board”). Immediately after the 2018 Annual Meeting, the Board approved a one-for-five (1:5) reverse stock split of the outstanding shares of the BIOLASE common stock. On May 10, 2018, the Company filed an amendment (the “Fourth Amendment”) to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the reverse stock split and to reduce the authorized shares of common stock from 200,000,000 shares to 40,000,000 shares. Except as the context otherwise requires, all current and prior year share numbers (including common stock warrants) and share price amounts (including exercise prices and closing market prices) contained in these audited financial statements and notes thereto reflect the one-for-five reverse stock split. Additionally, in 2018 the Company recorded a reclassification of $0.1 million between common stock and additional paid-in capital, equal to the reduction in par value.
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
100000
CY2017Q4 biol Proceeds From Issuance Of Equity Net Of Issuance Costs
ProceedsFromIssuanceOfEquityNetOfIssuanceCosts
11400000
CY2017Q2 biol Proceeds From Issuance Of Equity Net Of Issuance Costs
ProceedsFromIssuanceOfEquityNetOfIssuanceCosts
10200000
CY2017Q3 biol Proceeds From Issuance Of Equity Net Of Issuance Costs
ProceedsFromIssuanceOfEquityNetOfIssuanceCosts
9500000
CY2019Q4 biol Proceeds From Common Stock Offering And Concurrent Private Placement
ProceedsFromCommonStockOfferingAndConcurrentPrivatePlacement
8200000
CY2019Q4 biol Cash And Cash Equivalents And Restricted Cash
CashAndCashEquivalentsAndRestrictedCash
6100000
CY2019 us-gaap Depreciation
Depreciation
1000000
CY2018 us-gaap Depreciation
Depreciation
900000
CY2019 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2018 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1200000
CY2017 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
500000
CY2019 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2019 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.81
CY2018 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.86
CY2017 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.85
CY2019 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.19
CY2018 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.14
CY2017 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.15
CY2019Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
559000
CY2018Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
730000
CY2019Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
2063000
CY2018Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
1735000
CY2018Q4 biol Contract With Customer Liability In Deferred Royalties
ContractWithCustomerLiabilityInDeferredRoyalties
11000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2622000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2476000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
385000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2237000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2476000
CY2019 biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
500000
CY2018 biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
800000
CY2019 biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
700000
CY2018 biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
800000
CY2019 biol Contract With Customer Liability Revenue Recognized Deferred Royalties
ContractWithCustomerLiabilityRevenueRecognizedDeferredRoyalties
0
CY2018 biol Contract With Customer Liability Revenue Recognized Deferred Royalties
ContractWithCustomerLiabilityRevenueRecognizedDeferredRoyalties
11000
CY2019 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1004000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1110000
CY2017Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
70000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
865000
CY2019 us-gaap Advertising Expense
AdvertisingExpense
500000
CY2018 us-gaap Advertising Expense
AdvertisingExpense
600000
CY2017 us-gaap Advertising Expense
AdvertisingExpense
600000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2742000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2768000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2207000
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2700000
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2800000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y6M14D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P8Y
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M13D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M3D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.85
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.81
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.79
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0255
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0254
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0199
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6922000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5862000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3384000
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
8760000
CY2018Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
10990000
CY2018Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
71000
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
51000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2600000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
900000
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3689000
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3590000
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1064000
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1435000
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6242000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7223000
CY2019Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1300000
CY2018Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1100000
CY2019Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
10353000
CY2018Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
10153000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9322000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8344000
CY2019Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1031000
CY2018Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
1809000
CY2019Q4 us-gaap Land
Land
162000
CY2018Q4 us-gaap Land
Land
166000
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1726000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2400000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
242000
CY2018Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
714000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
330000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1044000
CY2019Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
546000
CY2018Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
328000
CY2018Q4 biol Patent Litigation Settlement Current
PatentLitigationSettlementCurrent
1500000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
323000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
712000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
691000
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2800000
CY2018 biol Indefinite Lived Intangible Assets Useful Life
IndefiniteLivedIntangibleAssetsUsefulLife
indefinite life
CY2018Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2800000
CY2019 biol Indefinite Lived Intangible Assets Useful Life
IndefiniteLivedIntangibleAssetsUsefulLife
indefinite life
CY2019Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
23000
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
73000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
96000
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-12000
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-128000
CY2019 biol Deferred Income Tax Expense Benefit Adjustment
DeferredIncomeTaxExpenseBenefitAdjustment
-140000
CY2018 biol Deferred Income Tax Expense Benefit Adjustment
DeferredIncomeTaxExpenseBenefitAdjustment
-41000
CY2017 biol Deferred Income Tax Expense Benefit Adjustment
DeferredIncomeTaxExpenseBenefitAdjustment
-694000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.350
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.286
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.906
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.070
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.031
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.032
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.021
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.017
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.017
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.024
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.003
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.010
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.200
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.005
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-1.271
CY2019 biol Effective Income Tax Rate Reconciliation Expired Net Operating Loss Carryforwards
EffectiveIncomeTaxRateReconciliationExpiredNetOperatingLossCarryforwards
-0.107
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.026
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.033
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.020
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.034
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
-38000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
-42000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1384000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
1666000
CY2019Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
44000
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
38000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4694000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4153000
CY2019Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
5000
CY2018Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
5000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3429000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
3820000
CY2019Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
974000
CY2018Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
549000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
302000
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
126000
CY2019Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
111000
CY2018Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
85000
CY2019Q4 biol Deferred Tax Assets Disallowed Interest
DeferredTaxAssetsDisallowedInterest
708000
CY2018Q4 biol Deferred Tax Assets Disallowed Interest
DeferredTaxAssetsDisallowedInterest
120000
CY2019Q4 biol Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
129000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42527000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
37205000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54269000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47725000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53222000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
46967000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1047000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
758000
CY2019Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
708000
CY2018Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
629000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
109000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
179000
CY2018Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
206000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
996000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
835000
CY2019Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.5750
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1322000
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
10836000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2100000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
2800000
CY2019Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
10100000
CY2019Q4 biol Long Term Debt Maturities Repayments Of Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths
1873000
CY2019Q4 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
7593000
CY2019 biol Operating Loss Carryforwards Expirations Period
OperatingLossCarryforwardsExpirationsPeriod
2037
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
509000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2019 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
509000
CY2019Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
600000
CY2019 biol Current Inome Related To Global Intangible Low Taxed Income
CurrentInomeRelatedToGlobalIntangibleLowTaxedIncome
100000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15000000
CY2018Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
12500000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1534000
CY2018Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1664000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
13466000
CY2019Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2019 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2019Q4 biol Lease Facility Area
LeaseFacilityArea
57000
CY2019 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-06-30
CY2019 biol Lease Agreement Entry Date
LeaseAgreementEntryDate
2020-02
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1278
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
797000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
803000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7M6D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.128
CY2019 us-gaap Lessee Operating Lease Lease Not Yet Commenced Description
LesseeOperatingLeaseLeaseNotYetCommencedDescription
As of December 31, 2019 the Company had no leases that had not commenced.
CY2019 biol Lessee Operating Lease Number Of Lease Not Yet Commenced
LesseeOperatingLeaseNumberOfLeaseNotYetCommenced
0
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
326000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
342000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
16000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
326000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
802000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
313000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
33000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1148000
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2019Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
9800000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2019 biol Dividend Declared
DividendDeclared
0
CY2018 biol Dividend Declared
DividendDeclared
0
CY2017 biol Dividend Declared
DividendDeclared
0
CY2017 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
446000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
421000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1347000
CY2018 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
611000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
334000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1623000
CY2019 biol Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period At Fair Market Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAtFairMarketValue
90000
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
424000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1287000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1033000
CY2019 biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod
224000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.60
CY2017 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
5.15
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.30
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.15
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.99
CY2018 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
1.98
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.10
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.68
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.54
CY2019 biol Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price At Fair Market Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceAtFairMarketValue
1.74
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.10
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.43
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.77
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.58
CY2019 biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice
9.91
CY2019Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1286811000
CY2019Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.77
CY2019 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y9M21D
CY2019Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
1032872000
CY2019Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
6.58
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.51
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.38
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.45
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
587000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1191000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1286000
CY2018Q2 biol Number Of New Board Members
NumberOfNewBoardMembers
2
CY2017Q2 biol Number Of Vice Presidents
NumberOfVicePresidents
1
CY2017Q1 biol Number Of Senior Vice President And Chief Financial Officer
NumberOfSeniorVicePresidentAndChiefFinancialOfficer
1
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3674000

Files In Submission

Name View Source Status
0001564590-20-013794-index-headers.html Edgar Link pending
0001564590-20-013794-index.html Edgar Link pending
0001564590-20-013794.txt Edgar Link pending
0001564590-20-013794-xbrl.zip Edgar Link pending
biol-10k_20191231.htm Edgar Link pending
biol-20191231.xml Edgar Link completed
biol-20191231.xsd Edgar Link pending
biol-20191231_cal.xml Edgar Link unprocessable
biol-20191231_def.xml Edgar Link unprocessable
biol-20191231_lab.xml Edgar Link unprocessable
biol-20191231_pre.xml Edgar Link unprocessable
biol-ex1012_499.htm Edgar Link pending
biol-ex1013_556.htm Edgar Link pending
biol-ex1029_500.htm Edgar Link pending
biol-ex211_8.htm Edgar Link pending
biol-ex231_10.htm Edgar Link pending
biol-ex311_11.htm Edgar Link pending
biol-ex312_12.htm Edgar Link pending
biol-ex321_6.htm Edgar Link pending
biol-ex322_9.htm Edgar Link pending
biol-ex49_501.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ghcenyhb23cn000001.jpg Edgar Link pending
ghcenyhb23cn000002.jpg Edgar Link pending
ghcenyhb23cn000003.jpg Edgar Link pending
ghcenyhb23cn000004.jpg Edgar Link pending
ghcenyhb23cn000005.jpg Edgar Link pending
ghcenyhb23cn000006.jpg Edgar Link pending
ghcenyhb23cn000007.jpg Edgar Link pending
ghcenyhb23cn000008.jpg Edgar Link pending
ghcenyhb23cn000009.jpg Edgar Link pending
ghcenyhb23cn000010.jpg Edgar Link pending
ghcenyhb23cn000011.jpg Edgar Link pending
ghcenyhb23cn000012.jpg Edgar Link pending
ghcenyhb23cn000013.jpg Edgar Link pending
ghcenyhb23cn000014.jpg Edgar Link pending
ghcenyhb23cn000015.jpg Edgar Link pending
ghcenyhb23cn000016.jpg Edgar Link pending
ghcenyhb23cn000017.jpg Edgar Link pending
ghcenyhb23cn000018.jpg Edgar Link pending
ghcenyhb23cn000019.jpg Edgar Link pending
ghcenyhb23cn000020.jpg Edgar Link pending
ghcenyhb23cn000021.jpg Edgar Link pending
ghcenyhb23cn000022.jpg Edgar Link pending
ghcenyhb23cn000023.jpg Edgar Link pending
ghcenyhb23cn000024.jpg Edgar Link pending
ghcenyhb23cn000025.jpg Edgar Link pending
ghcenyhb23cn000026.jpg Edgar Link pending
ghcenyhb23cn000027.jpg Edgar Link pending
ghcenyhb23cn000028.jpg Edgar Link pending
ghcenyhb23cn000029.jpg Edgar Link pending
ghcenyhb23cn000030.jpg Edgar Link pending
ghcenyhb23cn000031.jpg Edgar Link pending
ghcenyhb23cn000032.jpg Edgar Link pending
ghcenyhb23cn000033.jpg Edgar Link pending
ghcenyhb23cn000034.jpg Edgar Link pending
ghcenyhb23cn000035.jpg Edgar Link pending
ghcenyhb23cn000036.jpg Edgar Link pending
ghcenyhb23cn000037.jpg Edgar Link pending
ghcenyhb23cn000038.jpg Edgar Link pending
ghcenyhb23cn000039.jpg Edgar Link pending
ghcenyhb23cn000040.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending